Compare BioNano Genomics Inc (BNGO) vs Credo Technology Group Holding Ltd (CRDO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Credo Technology Group Holding Ltd — how do they compare? BioNano Genomics Inc trades at $1.2 (market cap $13.66M), while Credo Technology Group Holding Ltd trades at $275.72 (market cap $46.19B). The key difference: Credo Technology Group Holding Ltd is far larger — about 3381.4× BioNano Genomics Inc's market cap, and Credo Technology Group Holding Ltd is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.
| BNGO | CRDO | |
|---|---|---|
Market Cap | $13.66M | $46.19B |
Sector | Health | Technology |
52-Week High | $4.92 | $302.52 |
52-Week Low | $1.06 | $87.81 |
Enterprise Value | $16.26M | $44.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.19, up 2.59% today, with bullish technical signals from moving averages. The company shows improving financials with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable. Recent earnings have consistently beaten expectations, and analyst sentiment is positive with 57% buy ratings. Key developments include debt retirement and scientific publications highlighting optical genome mapping adoption.
The outlook is cautiously optimistic given improving fundamentals and positive analyst coverage, but significant risks remain due to persistent losses and negative cash flow. Investment opportunity lies in the company's technology adoption growth, while primary risks include profitability challenges and competitive pressures in the genomics space.
CRDO trades at $275.98, up 15.02% in 24 hours, reflecting strong momentum. Technical indicators show a bullish trend with support at $243 and resistance at $250. The company reported robust earnings, beating estimates in Q3 2025, Q4 2025, and Q1 2026, with revenue surging 157% year-over-year in Q4 2025. Analyst consensus is strongly bullish, with 13 buy ratings and a price target of $285.42. Recent news highlights AI infrastructure demand driving growth, including contributions to the Open Compute Project.
Outlook is positive due to AI-driven demand and strong financial performance, but risks include high valuation multiples and customer concentration. The stock offers growth potential, yet investors should monitor execution risks and market volatility. Upside is supported by analyst targets, while downside protection exists near support levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Credo Technology Group Holding Ltd
Credo Technology provides high-speed connectivity solutions for AI-driven applications and hyperscale data centers. Its products enable faster, more energy-efficient data transmission for cloud and telecom infrastructure.
Read more on CRDO →
